These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20727052)

  • 1. Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
    Tomita Y
    Int J Urol; 2010 Sep; 17(9):815-6. PubMed ID: 20727052
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib rechalenge in metastatic renal cell carcinoma.
    Porta C; Paglino C; Imarisio I
    BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Raspollini MR
    Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
    Wu Y; Zhao Y
    Int J Urol; 2011 Jun; 18(6):430-1. PubMed ID: 21599760
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment.
    Rini BI; Shah SN
    Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment.
    Vaishampayan U
    Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract]   [Full Text] [Related]  

  • 7. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S; Hertle L; Nitschmann S
    Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
    [No Abstract]   [Full Text] [Related]  

  • 8. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 10. A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis.
    Benincasa E; Conti A; Bossone G; Gallà DA; Gianciotta A; Zuccaro SM; Madaio R
    Tumori; 2009; 95(3):403. PubMed ID: 19688987
    [No Abstract]   [Full Text] [Related]  

  • 11. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE; Rini BI; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y
    Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
    Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
    Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
    [No Abstract]   [Full Text] [Related]  

  • 16. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
    Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
    Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting renal cell carcinoma.
    Motzer RJ; Molina AM
    J Clin Oncol; 2009 Jul; 27(20):3274-6. PubMed ID: 19451422
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
    Lekili M; Muezzinoglu T; Nese N; Temeltas G
    J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
    Valcamonico F; Ferrari V; Amoroso V; Rangoni G; Simoncini E; Marpicati P; Vassalli L; Grisanti S; Marini G
    J Neurooncol; 2009 Jan; 91(1):47-50. PubMed ID: 18712279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized discontinuation trial of sorafenib (BAY 43-9006).
    Jain L; Venitz J; Figg WD
    Cancer Biol Ther; 2006 Oct; 5(10):1270-2. PubMed ID: 16969070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.